Kimball Electronics has acquired Helvoet Polymer Technologies, expanding its medical contract development and manufacturing capability across Europe and India.
The transaction values Helvoet at around €90m and adds specialist capacity in micro-moulding and precision injection moulding for medical applications. Helvoet operates from Tilburg in the Netherlands and Pune in India, with capabilities focused on microfluidics, diagnostics, and drug delivery.
Kimball Electronics expects the acquisition to strengthen its medical vertical and to be accretive to fiscal 2027 adjusted earnings. The company’s existing Indianapolis facility is expected to support Helvoet’s US customers, giving the enlarged business a broader manufacturing footprint across North America, Europe, and India.
The deal places Kimball deeper into a part of medical technology where precision plastics, electronics, fluid control, and regulated manufacturing increasingly overlap. Diagnostics and drug delivery products often depend on very small polymer components with tight tolerances, controlled materials, reliable sealing behaviour, and repeatable production quality.
Microfluidic devices are particularly demanding because they use small channels, chambers, membranes, and interfaces to manipulate tiny volumes of fluid inside diagnostic cartridges, lab-on-chip systems, or drug delivery platforms. Manufacturing errors that appear insignificant at conventional scale can affect flow behaviour, test performance, dosing accuracy, or device reliability.
Micro-moulding is therefore a specialist discipline rather than a standard plastics process. Tooling, material selection, mould temperature, flow behaviour, part ejection, metrology, clean manufacturing, assembly, and inspection all have to be tightly controlled. In medical markets, those technical requirements sit alongside documentation, validation, traceability, and regulatory compliance.
The acquisition reflects wider consolidation in medtech manufacturing. Medical device companies increasingly want CDMO partners that can support development, industrialisation, production, supply chain management, and regional manufacturing access. A supplier able to combine electronics, plastics, assembly, and quality systems becomes more valuable as devices integrate sensors, connectivity, diagnostics, and controlled delivery functions.
Kimball Electronics already operates in electronics manufacturing and complex product assembly. Helvoet adds a stronger polymer and micro-moulding dimension, allowing the company to support customers at the interface between electromechanical devices and precision moulded medical components. That interface is becoming more important as diagnostics platforms and drug delivery systems become smaller, smarter, and more integrated.
Medical technology launches are increasingly blending hardware, imaging, electronics, software, and workflow, as shown by Olympus’ ENDOEYE ULTRA platform. Kimball’s acquisition speaks to the manufacturing side of the same pattern, where products with greater technical density require suppliers with multiple capabilities under controlled quality systems.
The European footprint is significant. Medical device companies often want regional manufacturing options to manage supply risk, regulatory requirements, customer proximity, and resilience. A Dutch manufacturing base gives Kimball stronger access to Europe’s medtech and life sciences clusters, while the Indian operation adds cost-competitive production and proximity to a fast-growing healthcare manufacturing market.
Medical supply chains remain under scrutiny after pandemic-era disruption exposed weaknesses in single-source supply, long logistics routes, and limited surge capacity. Although the market has normalised, buyers continue to assess suppliers on resilience, compliance maturity, and geographic flexibility as well as unit cost.
Integration will need to be handled carefully. Medical customers value stability, and CDMO acquisitions can create risk if systems, quality processes, management structures, or customer support change too quickly. Kimball will need to combine Helvoet’s specialist capability with its wider manufacturing platform while preserving the process discipline and customer relationships that made the acquisition attractive.
The transaction strengthens Kimball’s position in a medtech market where devices are getting smaller, more regulated, and more manufacturing-intensive. Growth in diagnostics, microfluidics, and drug delivery will continue to reward suppliers that can turn precision engineering into repeatable production.
